CN1704062A - 齐墩果酸缓释片及其制备方法 - Google Patents
齐墩果酸缓释片及其制备方法 Download PDFInfo
- Publication number
- CN1704062A CN1704062A CN 200410044333 CN200410044333A CN1704062A CN 1704062 A CN1704062 A CN 1704062A CN 200410044333 CN200410044333 CN 200410044333 CN 200410044333 A CN200410044333 A CN 200410044333A CN 1704062 A CN1704062 A CN 1704062A
- Authority
- CN
- China
- Prior art keywords
- oleanolic acid
- slow releasing
- releasing tablet
- eudragit
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 title claims abstract description 41
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 title claims abstract description 41
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 title claims abstract description 41
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 229940100243 oleanolic acid Drugs 0.000 title claims abstract description 41
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000007939 sustained release tablet Substances 0.000 title abstract 2
- 239000000314 lubricant Substances 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 10
- 239000004094 surface-active agent Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 17
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 10
- 238000007907 direct compression Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 239000001856 Ethyl cellulose Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims description 6
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 6
- 229920001249 ethyl cellulose Polymers 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 229960003943 hypromellose Drugs 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 4
- 229920003156 Eudragit® RL PO Polymers 0.000 claims description 3
- 229920003160 Eudragit® RS PO Polymers 0.000 claims description 3
- 238000007906 compression Methods 0.000 claims description 3
- 230000006835 compression Effects 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- 229920003155 Eudragit® RL 100 Polymers 0.000 claims description 2
- 229920003157 Eudragit® RL 30 D Polymers 0.000 claims description 2
- 229920003159 Eudragit® RS 100 Polymers 0.000 claims description 2
- 229920003161 Eudragit® RS 30 D Polymers 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- -1 Stepanol MG Chemical compound 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 238000005550 wet granulation Methods 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 abstract description 8
- 239000004067 bulking agent Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 description 5
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410044333 CN100522175C (zh) | 2004-05-26 | 2004-05-26 | 齐墩果酸缓释片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410044333 CN100522175C (zh) | 2004-05-26 | 2004-05-26 | 齐墩果酸缓释片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1704062A true CN1704062A (zh) | 2005-12-07 |
CN100522175C CN100522175C (zh) | 2009-08-05 |
Family
ID=35575783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410044333 Expired - Fee Related CN100522175C (zh) | 2004-05-26 | 2004-05-26 | 齐墩果酸缓释片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100522175C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102106860A (zh) * | 2010-09-27 | 2011-06-29 | 林秀坤 | 齐墩果酸的抗肝癌作用及其药物制剂 |
CN102114023A (zh) * | 2010-09-27 | 2011-07-06 | 林秀坤 | 齐墩果酸的抗卵巢癌作用及其药物制剂 |
CN102114021A (zh) * | 2010-09-27 | 2011-07-06 | 林秀坤 | 齐墩果酸的抗乳腺癌作用及其药物制剂 |
CN102114022A (zh) * | 2010-09-27 | 2011-07-06 | 林秀坤 | 齐墩果酸的抗结肠癌作用及其药物制剂 |
CN102133219A (zh) * | 2010-09-27 | 2011-07-27 | 林秀坤 | 齐墩果酸的抗***作用及其药物制剂 |
CN102151275A (zh) * | 2010-11-07 | 2011-08-17 | 林秀坤 | 齐墩果酸的抗胰腺癌作用及其药物制剂 |
-
2004
- 2004-05-26 CN CN 200410044333 patent/CN100522175C/zh not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102106860A (zh) * | 2010-09-27 | 2011-06-29 | 林秀坤 | 齐墩果酸的抗肝癌作用及其药物制剂 |
CN102114023A (zh) * | 2010-09-27 | 2011-07-06 | 林秀坤 | 齐墩果酸的抗卵巢癌作用及其药物制剂 |
CN102114021A (zh) * | 2010-09-27 | 2011-07-06 | 林秀坤 | 齐墩果酸的抗乳腺癌作用及其药物制剂 |
CN102114022A (zh) * | 2010-09-27 | 2011-07-06 | 林秀坤 | 齐墩果酸的抗结肠癌作用及其药物制剂 |
CN102133219A (zh) * | 2010-09-27 | 2011-07-27 | 林秀坤 | 齐墩果酸的抗***作用及其药物制剂 |
CN102151275A (zh) * | 2010-11-07 | 2011-08-17 | 林秀坤 | 齐墩果酸的抗胰腺癌作用及其药物制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN100522175C (zh) | 2009-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5503845A (en) | Tablets, granulates and pellets with a high active substance content for highly concentrated, solid dosage forms | |
CN1248690C (zh) | 一种治疗心血管疾病含盐酸雷诺嗪的口服制剂 | |
CN1092963C (zh) | 解酸组合物和药物组合物 | |
CN1704062A (zh) | 齐墩果酸缓释片及其制备方法 | |
CN101077343A (zh) | 右旋布洛芬颗粒及制备方法 | |
CN1742741A (zh) | 含氨基葡萄糖和钙剂及维生素d的药物组合物及其应用 | |
CN1225241C (zh) | 一种口腔崩解片的制备方法 | |
CN1876009A (zh) | 三七止血咀嚼片及其制备方法 | |
CN102327266A (zh) | 一种含有伊潘立酮的药物组合物及其制备方法 | |
CN1840010A (zh) | 一种治疗胃病的微丸及其制备方法 | |
CN1287797C (zh) | 更昔洛韦分散片及其制备方法 | |
CN103110601B (zh) | 一种格列齐特胃漂浮片及其制备方法 | |
CN1839835A (zh) | 一种拉西地平药物制剂的制备方法 | |
CN1857289A (zh) | 一种复方甘草酸及其盐的分散片剂及其制备方法 | |
CN1723913A (zh) | 一种辅酶a舌下含片的制备方法 | |
CN101040850A (zh) | 秋水仙碱缓释微丸及制备方法 | |
CN102258493A (zh) | 红景天苷缓释片及其制备方法 | |
CN1526384A (zh) | 非诺贝特快速崩解的口服制剂 | |
CN1692909A (zh) | 多司马酯分散片及其制备办法 | |
CN1049114C (zh) | 一种制备缓释药物制剂的方法 | |
CN1698792A (zh) | 裸花紫珠分散片及其制备方法 | |
CN102349882A (zh) | 一种含有群多普利的药物组合物及其制备方法 | |
CN101152142A (zh) | 含2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸的固体药物组合物 | |
CN1872160A (zh) | 丹参缓释片及制备工艺 | |
CN1923166A (zh) | 卡维地洛控释制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: HANGZHOU MINSHENG MEDCINE CO., LTD. Free format text: FORMER NAME: HANGZHOU MINSHENG PHARMACEUTICAL GROUP CO. |
|
CP03 | Change of name, title or address |
Address after: No. 108 Tong Road, Hangzhou, Zhejiang, Yuhang Patentee after: Hangzhou Minsheng Pharmaceutical Co., Ltd. Address before: No. 108 Tong Road, Hangzhou, Zhejiang, Yuhang Patentee before: Hangzhou Minsheng Pharmaceutical Group Co., Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU RENHENG PHARMACEUTICAL TECHNOLOGY CO., L Free format text: FORMER OWNER: HANGZHOU MINSHENG PHARMACEUTICAL CO., LTD. Effective date: 20150528 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310011 HANGZHOU, ZHEJIANG PROVINCE TO: 510305 GUANGZHOU, GUANGDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150528 Address after: 510305 west side of the third floor of A4 building, 171 Haizhuqu District Road, Guangdong, Guangzhou Patentee after: Guangzhou Ren Heng Pharmaceutical Technology Co., Ltd Address before: 310011 No. 108 Tong Road, Hangzhou, Zhejiang, Yuhang Patentee before: Hangzhou Minsheng Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090805 Termination date: 20160526 |
|
CF01 | Termination of patent right due to non-payment of annual fee |